Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of vactosertib plus pembrolizumab in acral and mucosal melanoma after prior checkpoint inhibitor
KCT0007745Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vactosertib, pembrolizumab in acral lentiginous melanoma (ALM), mucosal melanoma (MM), sponsored by Merck & Co.. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
vactosertibpembrolizumab
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on KCT0007745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007745.